Your Health, We Care
Release date: 2026-05-22 14:08:15 Article From: Lucius Laos Recommended: 14
Brigatinib must be taken exactly as directed by your doctor or pharmacist. The recommended dosage is given in two phases: for the first 7 days of treatment, take 90 mg once daily (one tablet); from day 8 onward, take 180 mg once daily (one tablet). Do not change the dose on your own. Your doctor may adjust the dose based on individual tolerability and response, for example by using 30 mg tablets to achieve the new required dose. To facilitate initiation of treatment, a starter pack is available: each outer pack contains two inner packs, with seven 90 mg tablets and twenty‑one 180 mg tablets respectively. The required dose is printed on the pack, please check carefully.
Take brigatinib at the same time each day. Swallow the tablet whole with a full glass of water; do not crush or dissolve. The tablet may be taken with or without food. If vomiting occurs after taking the dose, do not take an extra dose; simply take the next scheduled dose at the usual time. If you forget to take a dose, do not double the next dose to make up for it, just take the next dose as planned. If you take more tablets than the recommended dose, tell your doctor or pharmacist immediately. Special reminder: do not swallow the desiccant capsule inside the bottle. Do not stop treatment without your doctor’s approval.
Store brigatinib out of the sight and reach of children. This medicine does not require any special storage conditions; keep at room temperature. Do not use the medicine after the expiry date, which is indicated on the container label, blister card or outer pack after “EXP”, meaning the last day of that month. For expired or no longer needed medicine, ask your pharmacist how to dispose of it properly. To protect the environment, do not discard medicine residues in the sink, toilet or ordinary rubbish bin. Dispose of them according to local regulations or via pharmacy take‑back schemes.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：3542025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：5532024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3432025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：3552025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：3302025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：3982025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3282025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：3032025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
